IGI Logo

Shilpa Medicare is currently trading at Rs. 760.75, up by 28.15 points or 3.84% from its previous closing of Rs. 732.60 on the BSE.

The scrip opened at Rs. 743.05 and has touched a high and low of Rs. 798.00 and Rs. 741.75 respectively. So far 122239 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 798.00 on 27-Aug-2024 and a 52 week low of Rs. 296.45 on 26-Oct-2023.

Last one week high and low of the scrip stood at Rs. 798.00 and Rs. 687.30 respectively. The current market cap of the company is Rs. 7432.11 crore.

The promoters holding in the company stood at 44.39%, while Institutions and Non-Institutions held 16.69% and 38.92% respectively.

Shilpa Medicare has received the approval for its second NDA (505(b)(2)), injectable product - Bortezomib Injection, from USFDA. Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL).

This is the first liquid injection for Bortezomib, approved for both subcutaneous and intravenous administration by the USFDA. The Injection is ‘ready to use’ for subcutaneous administration, offering significant advantages to the health care providers. The Injection has to be diluted for intravenous use. The reference product Velcade is a lyophilized injection which requires reconstitution prior to administration.

Bortezomib Injection, a proteasome inhibitor, contains bortezomib which is an antineoplastic agent. This NDA provides for the use of Bortezomib injection for the treatment of adult patients with multiple myeloma and for the treatment of adult patients with mantle cell lymphoma.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.